2022 Annual Business Report

Addressing unmet
medical needs


Vaccine development at Valneva

"At Valneva, we take a specialized approach to vaccine development, focusing on disease targets that lack a preventative or therapeutic solution"

Juan Caros Jaramillo MD, Chief Medical Officer

Investments 2022

Our clinical vaccine pipeline

Our clinical vaccine pipeline

Our current clinical portfolio is composed of a number of highly differentiated vaccine candidates that are designed to provide preventative solutions to diseases with high unmet need.


Chikungunya – VLA1553

Chikungunya – VLA1553

VLA1553 is a single-shot vaccine candidate against chikungunya, a mosquito-borne disease that is highly prevalent in tropical and subtropical regions.


Franck GrimaudDirecteur Général & Chief Business Officer

Lyme Disease  – VLA15

Lyme Disease – VLA15

VLA15 is the only vaccine in advanced clinical development against Lyme disease, the most common tick-borne infection in the northern hemisphere.

Pre-clinical assets

Pre-clinical assets

In addition to our clinical portfolio, we are advancing select pre-clinical assets.